Astellas Pharma's logo is pictured at its headquarters in Tokyo, Japan, December 3, 2019. REUTERS/Kim Kyung-Hoon Purchase Licensing Rights, opens new tab ...

Astellas Pharma's logo is pictured at its headquarters in Tokyo, Japan, December 3, 2019. REUTERS/Kim Kyung-Hoon/File Photo Purchase Licensing Rights, opens new tab ...

- Agreement covers the co-development and co-commercialization of up to three T-cell therapies - - Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell ...

- Acquire PRL-02, prostate cancer treatment program being developed by Propella Therapeutics -TOKYO and PITTSBORO, N.C., Nov. 15, 2023 /PRNewswire ...

In the Acquisition, Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. The total equity value of Iveric Bio in the Acquisition assumes that there are approximately 148.2 ...